By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Novartis has signed a definitive agreement to acquire personalized diagnostics lab services firm Genoptix for approximately $470 million.

Novartis will pay $25 per share in cash for all of the outstanding shares of the Carlsbad, Calif.-based company. The purchase price represents an approximately 27 percent premium to Genoptix's Friday closing price on the Nasdaq of $19.76.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.